Dextromoramide

Last updated
Dextromoramide
Dextromoramide2DACS.svg
Clinical data
Trade names Palfium
AHFS/Drugs.com International Drug Names
Pregnancy
category
  • AU:C
Routes of
administration
Oral, Rectal, Intravenous, Insufflation [1]
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability >75% [3]
Protein binding High [3]
Metabolism Liver, partly mediated by CYP3A4 [3]
Elimination half-life 3.5 hours [3]
Excretion Urine, faeces [3]
Identifiers
  • (3S)-3-methyl-4-morpholin-4-yl-2,2-diphenyl-1-pyrrolidin-1-yl-butan-1-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.006.013 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C25H32N2O2
Molar mass 392.543 g·mol−1
3D model (JSmol)
  • C[C@H](CN1CCOCC1)C(C(=O)N1CCCC1)(c1ccccc1)c1ccccc1
  • InChI=1S/C25H32N2O2/c1-21(20-26-16-18-29-19-17-26)25(22-10-4-2-5-11-22,23-12-6-3-7-13-23)24(28)27-14-8-9-15-27/h2-7,10-13,21H,8-9,14-20H2,1H3/t21-/m1/s1 Yes check.svgY
  • Key:INUNXTSAACVKJS-OAQYLSRUSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Dextromoramide [4] (Palfium, Palphium, Jetrium, Dimorlin) [5] is a powerful opioid analgesic approximately three times more potent than morphine but shorter acting. [6] It is subject to drug prohibition regimes, both internationally through UN treaties and by the criminal law of individual nations, and is usually prescribed only in the Netherlands.

Contents

History

Dextromoramide was discovered and patented in 1956 by Paul Janssen at Janssen Pharmaceuticals, who also discovered fentanyl, another important synthetic opioid, widely used to treat pain and in combination with other drugs as an anaesthetic, as well as haloperidol, piritramide, the loperamide-diphenoxylate series and other important drugs. [7]

Dextromoramide was much favoured by drug users in Australia in the 1970s and the United Kingdom. [8] It has the main proprietary name of Palfium amongst others, though as of mid-2004 the drug was discontinued in the UK due to limited supplies of precursor chemicals. Although this is true, it is believed there was an approximate one year shortage of Dextromoramide and the real reason that Palfium was not put back into production for the UK market is because of how addictive and potent it is as an oral painkiller.[ citation needed ] Dependence liability is similar to morphine, but with a less severe withdrawal syndrome.

The only European countries that now use the brand Palfium are the Netherlands, Ireland and Luxembourg. It is presumably able to be imported into other Schengen zone countries under Title 76 of said treaty coming into force in 2002.[ citation needed ] It is a Schedule I Narcotic controlled substance in the United States, with a DEA ACSCN of 9613 and an annual aggregate manufacturing quota of zero as of 2013, and had been out of use in the United States for around a decade when the new Controlled Substances Act 1970 was promulgated. The salts of dextromoramide in use are the hydrochloride (free base conversion ratio 0.915) and tartrate (0.724). [9] Racemoramide and moramide intermediate are also controlled.

Medical use

The main advantage of this drug is that it has a fast onset of action when taken orally, and has a high bioavailability which means that oral dosing produces almost as much effect as injection. It also has a relatively low tendency to cause constipation which is a common problem with opioid analgesics used for cancer pain relief, and tolerance to the analgesic effects develops relatively slowly compared to most other short-acting opioids. [10]

Pharmacokinetics

Dextromoramide has a mean elimination half life of 215.3 ± 78.4 minutes and volume of distribution of 0.58 ± 0.20 L/kg. [11] Peak plasma levels are reached within 0.5–4.0 h after dosing, decline of plasma concentrations after the peak follow a biphasic pattern, with half-lives of 0.4–1.6 h for the first phase and 6.3–21.8 h for the terminal phase. While in about 40% of patients, half-lives range from 1.5 to 4.7 h, in a monophasic manner. Less than 0.06% of the dose is excreted unchanged in urine within 8 h of administration. [12]

Chemistry

Dextromoramide is the right-handed isomer of the moramide molecule. The left-handed molecule is called levomoramide, and a mixture of the two is called racemoramide. Its full chemical name is (+)-1-(3-Methyl-4-morpholino-2,2-diphenylbutyryl)pyrrolidine, and its molecular formula: C25H32N2O2, with an atomic weight of ~392.5.

Dextromoramide was discovered during the course of research into a related family of compounds, the α,α-Diphenyl-γ-Dialkyamino-Butyramides, which show no analgesic activity, but are extremely active physiologically as inhibitors of gastric secretions in man. Other drugs from this series show antispasmodic and antihistamine effects, but most research was put into researching analgesics.

The structure-activity relationships of this family of drugs was investigated extensively, with dextromoramide representing the optimisation of several different structural features;

(i) at the 1-amide group only the pyrrolidine and dimethylamide substituents were active, with pyrrolidine being more potent

(ii) the alkyl chain was more potent when methylated, 3-methylation was more potent than 4-methylation, and in the 3-methyl analogues the dextro isomer was more active

(iii) while morpholine, dimethylamine, pyrrolidine and piperidine were all active at the 4-amine group, morpholine was the most active

(iv) any substitution on the phenyl rings reduces activity.

So dextromoramide, with a pyrrolidine ring on the 1-amide position, a dextro methyl group on the 3-position of the alkyl chain, a morpholine ring around the 4-amine group, and both phenyl rings unsubstituted, was by far the most potent out of all the compounds in this series and was the only one that became widely used in medicine (although the racemic mix racemoramide saw some limited use). [13]

Related Research Articles

<span class="mw-page-title-main">Morphine</span> Pain medication of the opiate family

Morphine, formerly also called morphia, is a strong opiate that is found naturally in opium, a dark brown resin produced by drying the latex of opium poppies. It is mainly used as an analgesic. There are numerous methods used to administer morphine: oral; sublingual; via inhalation; injection into a muscle, injection under the skin, or injection into the spinal cord area; transdermal; or via rectal suppository. It acts directly on the central nervous system (CNS) to induce analgesia and alter perception and emotional response to pain. Physical and psychological dependence and tolerance may develop with repeated administration. It can be taken for both acute pain and chronic pain and is frequently used for pain from myocardial infarction, kidney stones, and during labor. Its maximum effect is reached after about 20 minutes when administered intravenously and 60 minutes when administered by mouth, while the duration of its effect is 3–7 hours. Long-acting formulations of morphine are available as MS-Contin, Kadian, and other brand names as well as generically.

<span class="mw-page-title-main">Carfentanil</span> Synthetic opioid analgesic

Carfentanil or carfentanyl, sold under the brand name Wildnil, is an extremely potent opioid analgesic used in veterinary medicine to anesthetize large animals such as elephants and rhinoceroses. It is typically administered in this context by tranquilizer dart. Carfentanil has also been used in humans to image opioid receptors. It has additionally been used as a recreational drug, typically by injection, insufflation, or inhalation. Deaths have been reported in association with carfentanil.

<span class="mw-page-title-main">Phendimetrazine</span> Pharmaceutical drug

Phendimetrazine is a stimulant drug of the morpholine chemical class used as an appetite suppressant.

<span class="mw-page-title-main">Nalbuphine</span> Opioid analgesic

Nalbuphine, sold under the brand names Nubain among others, is an opioid analgesic which is used in the treatment of pain. It is given by injection into a vein, muscle, or fat.

<span class="mw-page-title-main">Dipipanone</span> Opioid analgesic drug

Dipipanone, sold under the brand names of Pipadone and Diconal is a strong opioid analgesic drug, used for acute pain by mouth (PO) for adults. It is often used in instances where morphine is indicated but cannot be used due to the patient being allergic to morphine. In analgesic potency 25 mg dipipanone is approximately equivalent to 10 mg morphine.

<span class="mw-page-title-main">Etonitazene</span> Chemical compound

Etonitazene, also known as EA-4941 or CS-4640, is a benzimidazole opioid, first reported in 1957, that has been shown to have approximately 1,000 to 1,500 times the potency of morphine in animals.

<span class="mw-page-title-main">Levorphanol</span> Opioid analgesic drug

Levorphanol is an opioid medication used to treat moderate to severe pain. It is the levorotatory enantiomer of the compound racemorphan. Its dextrorotatory counterpart is dextrorphan.

<span class="mw-page-title-main">Phenoperidine</span> Opioid analgesic drug

Phenoperidine, is an opioid analgesic which is structurally related to pethidine and is used clinically as a general anesthetic.

<span class="mw-page-title-main">Piritramide</span> Synthetic opioid

Piritramide(R-3365, trade names Dipidolor, Piridolan, Pirium and others) is a synthetic opioid analgesic that is marketed in certain European countries including: Austria, Belgium, Czech Republic, Slovenia, Germany and the Netherlands. It comes in free form, is about 0.75x times as potent as morphine and is given parenterally for the treatment of severe pain. Nausea, vomiting, respiratory depression and constipation are believed to be less frequent with piritramide than with morphine, and it produces more rapid-onset analgesia when compared to morphine and pethidine. After intravenous administration the onset of analgesia is as little as 1–2 minutes, which may be related to its great lipophilicity. The analgesic and sedative effects of piritramide are believed to be potentiated with phenothiazines and its emetic (nausea/vomiting-inducing) effects are suppressed. The volume of distribution is 0.7-1 L/kg after a single dose, 4.7-6 L/kg after steady-state concentrations are achieved and up to 11.1 L/kg after prolonged dosing.

<span class="mw-page-title-main">Ohmefentanyl</span> Opioid analgesic

Ohmefentanyl is an extremely potent opioid analgesic drug which selectively binds to the μ-opioid receptor.

<span class="mw-page-title-main">Phenadoxone</span> Opioid analgesic drug

Phenadoxone is an opioid analgesic of the open chain class invented in Germany by Hoechst in 1947. It is one of a handful of useful synthetic analgesics which were used in the United States for various lengths of time in the 20 or so years after the end of the Second World War but which were withdrawn from the market for various or no known reason and which now are mostly in Schedule I of the United States' Controlled Substances Act of 1970, or in Schedule II but not produced or marketed in the US. Others on this list are ketobemidone (Ketogin), dextromoramide, phenazocine, dipipanone, piminodine (Alvodine), propiram (Algeril), anileridine (Leritine) and alphaprodine (Nisentil).

<span class="mw-page-title-main">Levacetylmethadol</span> Synthetic opioid drug

Levacetylmethadol (INN), levomethadyl acetate (USAN), OrLAAM or levo-α-acetylmethadol (LAAM) is a synthetic opioid similar in structure to methadone. It has a long duration of action due to its active metabolites.

<span class="mw-page-title-main">Tapentadol</span> Opioid analgesic of benzenoid class

Tapentadol, brand names Nucynta among others, is a centrally acting opioid analgesic of the benzenoid class with a dual mode of action as an agonist of the μ-opioid receptor and as a norepinephrine reuptake inhibitor (NRI). Analgesia occurs within 32 minutes of oral administration, and lasts for 4–6 hours.

<span class="mw-page-title-main">Dezocine</span> Opioid analgesic

Dezocine, sold under the brand name Dalgan, is an atypical opioid analgesic which is used in the treatment of pain. It is used by intravenous infusion and intramuscular injection.

<span class="mw-page-title-main">Propiram</span> Opioid analgesic drug

Propiram is a partial μ-opioid receptor agonist and weak μ antagonist analgesic from the ampromide family of drugs related to other drugs such as phenampromide and diampromide. It was invented in 1963 in the United Kingdom by Bayer but was not widely marketed, although it saw some limited clinical use, especially in dentistry. Propiram reached Phase III clinical trials in the United States and Canada.

<span class="mw-page-title-main">PEPAP</span> Opioid analgesic drug

PEPAP (phenethylphenylacetoxypiperidine) is an opioid analgesic that is an analog of desmethylprodine.

<span class="mw-page-title-main">IC-26</span> Chemical compound

IC-26 is an analogue of the opioid analgesic methadone, where the carbonyl group has been replaced by the bioisosteric sulfone group.

An equianalgesic chart is a conversion chart that lists equivalent doses of analgesics. Equianalgesic charts are used for calculation of an equivalent dose between different analgesics. Tables of this general type are also available for NSAIDs, benzodiazepines, depressants, stimulants, anticholinergics and others.

<span class="mw-page-title-main">Arylcyclohexylamine</span> Class of chemical compounds

Arylcyclohexylamines, also known as arylcyclohexamines or arylcyclohexanamines, are a chemical class of pharmaceutical, designer, and experimental drugs.

<span class="mw-page-title-main">Desmethylmoramide</span> Opioid analgesic drug

Desmethylmoramide (INN) is an opioid analgesic related to dextromoramide that was synthesized and characterized in the late 1950s but was never marketed.

References

  1. Brayfield A, ed. (13 December 2013). "Dextromoramide". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 23 April 2014.
  2. Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  3. 1 2 3 4 5 "SAMENVATTING VAN DE PRODUCTKENMERKEN" (PDF). ACE Pharmaceuticals website (in Dutch). ACE Pharmaceuticals. January 2002. Retrieved 23 April 2014.[ permanent dead link ]
  4. GB Patent 822055 Improvements in or relating to new analgesically active substituted alpha, alpha-diphenyl--y-amino-butyramides and the manufacture thereof
  5. GB Patent 822055
  6. Twycross RG, Lack SA (1989). Oral morphine in advanced cancer (2nd ed.). Beaconsfield. ISBN   978-0-906584-27-9.
  7. López-Muñoz F, Alamo C (April 2009). "The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice". Brain Research Bulletin. 79 (2): 130–41. doi:10.1016/j.brainresbull.2009.01.005. PMID   19186209. S2CID   7720401.
  8. Newgreen DB (1980). "Dextromoramide: Review and Case Report". Australian Journal of Pharmacy. 61: 641–44.
  9. "Conversion Factors for Controlled Substances". Drug Enforcement Administration. U.S. Department of Justice. Archived from the original on 2016-03-02. Retrieved 2016-02-27.
  10. de Vos JW, Ufkes JG, van den Brink W, van Brussel GH, de Wolff FA (1999). "Craving patterns in methadone maintenance treatment with dextromoramide as adjuvant". Addictive Behaviors. 24 (5): 707–13. doi:10.1016/s0306-4603(98)00081-1. PMID   10574310.
  11. Lançon JP, Pechinot A, Athis PD, Pechinot M, Pointaire P, Obadia JF, Caillard B (1989). "[Pharmacokinetics of dextromoramide in the surgical patient]". Annales Françaises d'Anesthésie et de Réanimation. 8 (5): 488–92. doi:10.1016/s0750-7658(89)80015-2. PMID   2576345.
  12. Pagani I, Barzaghi N, Crema F, Perucca E, Ego D, Rovei V (1989). "Pharmacokinetics of dextromoramide in surgical patients". Fundamental & Clinical Pharmacology. 3 (1): 27–35. doi:10.1111/j.1472-8206.1989.tb00027.x. PMID   2714730. S2CID   39837195.
  13. Janssen PA (1960). Synthetic Analgesics Part 1: Diphenylpropylamines. Pergamon Press. pp. 141–145.

Further reading